Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Kaketsuken Suspends Shipments of 12 Products Due to Modifications of Approved Manufacturing Procedures
June 9, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 25 - June 7
June 8, 2015
- MHLW’s Jo Urges Generic Makers to Formulate Careful Investment Plans
June 8, 2015
- Govt Working Group Suspicious about Supply Limitation Hindering Generic Goal
June 8, 2015
- PAFSC 1st Committee Backs Approval of Lilly’s GLP-1 Receptor Agonist Dulaglutide
June 8, 2015
- 8 Members of PAFSC’s Pharmaceutical Affairs Council to Be Ousted for Violating COI Rules
June 8, 2015
- Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
- LDP Study Group Agrees on Good Balance between Generic Promotion, Innovation
June 5, 2015
- Prime Minister Abe Asks Health Minister to Formulate New Measures against Cancer by Year-End
June 4, 2015
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
- MHLW Calls for Revision of Package Insert for Xalkori
June 3, 2015
- MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
- MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
- JPMA Says Generic Target Has Huge Impact on Innovation, Balanced Approach Needed
June 1, 2015
- Lawmakers Tepid on Health Issues amid Weak Lobbying Campaigns on Generics, Drug Price Cuts
June 1, 2015
- AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
- MHLW’s Ryukaikon Council to Meet on June 17 to Review Distribution Conditions in FY2014
June 1, 2015
- 12 APIs/15 Products including Lantus Biosimilars Added to NHI Price List
May 29, 2015
- Gilead’s Combination Hep C Drug Likely to Win Japan Approval Late June
May 29, 2015
- Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo
May 28, 2015
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…